Inverness, Miraculins, Mount Sinai Hospital deal

Miraculins and Inverness partnered to develop and commercialize Miraculins' preeclampsia biomarker technology to detect preeclampsia, intrauterine growth and other pregnancy-related diseases. Inverness will develop and evaluate tests for the biomarkers and will receive an exclusive option to commercialize biomarkers of interest. Miraculins will retain commercialization rights to pursue complementary strategies for the biomarkers and will receive from Inverness rights to IP related to the biomarker endoglin ( CD105; ENG). Inverness has rights to use endoglin to develop diagnostics for preeclampsia under a July 2008 deal with the hospital. ...